Generics Bulletin l Pharma Intelligence

How it helps
A comprehensive and dependable information source available to ensure that industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities.

How it works
A broad network of global expert analysts and journalists you can rely on to provide valuable news and insight from tracking market events and their impacts from around the globe, to help you understand the potential impact of developments and trends on your business. Plus, access to exclusive interviews with key opinion leaders and market movers for insiders-knowledge to keep you ahead of the competition.

Analysis and opinion covers key topic areas such as:

Regulatory and compliance changes
Legal and legislations advances
Competitive developments
Merger and acquisition activities
New product launches
Marketing challenges
Advertising strategies, and more.

Start a free trial

Generics Bulletin

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

By David Wallace 25 Oct 2022

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Generics Bulletin

Medicines For Ireland Appoints New Chairs Following Framework Agreement

By Chloe Kent 18 Jan 2022

Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.

Generics Bulletin

Multiple Molecules See UK Prices More Than Double In December

By David Wallace 18 Jan 2022

WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

Generics Bulletin

Bio-Thera’s Bevacizumab US Action Date Passes Without Approval

By David Wallace 01 Dec 2021

GB2112_27_November_2021_Calendar_2GY47JX_1200

Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.

Generics Bulletin

ANI Pharmaceuticals Completes $210m Novitium Acquisition

By Chloe Kent 30 Nov 2021

GB2111_Handshake_Paper_Cutouts_E7N2BK_1200

ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.

Generics Bulletin

Teva And Endo Overcome Opioid Claims In California

By Dean Rudge 02 Nov 2021

Following a recent settlement in Louisiana, Teva has been told by a court in California it is not liable for the state’s opioid crisis, avoiding for now the potential for significant damages.

Generics Bulletin

EU’s Health Emergency Response Plans Must Address Existing Flaws

By David Wallace 17 Sep 2021

GB2109_EU_Flag_COVID_Coronavirus_2BD8JRX_1200

The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.

Generics Bulletin

MPP Celebrates First UMIC Dolutegravir Shipments

By David Wallace 14 Sep 2021

GB2109_Azerbaijan_Belarus_flags_2DMGYB5_1200

The Medicines Patent Pool has announced that the first shipments of dolutegravir under a fresh agreement covering upper-middle-income countries have reached Azerbaijan and Belarus.

Generics Bulletin

Alkem Delivers Strong Quarter With Domestic Recovery

By Akriti Seth 14 Sep 2021

GB2109_Graphs_Up_Arrows_Blue_Yellow_Green_TAWEXE_1200

India’s Alkem has delivered a strong quarter with a boost in its domestic business on the back of “strong volume-led growth in the acute therapies and faster than market growth in chronic therapies.” However, the company saw a slight YoY decline in the US.

Generics Bulletin

India Biosimilars Landscape

19 Aug 2021

India leads the ways with the highest number of approved biosimilars.

Generics Bulletin

Dr Reddy’s Gears For Sputnik Light In India, Jab For Adolescents

By Anju Ghangurde 30 Jul 2021

Dr Reddy’s is to press ahead with India filing plans for single-dose COVID-19 vaccine Sputnik Light and also expects to “build on” the Russian partner’s trial in adolescents of the two-dose Sputnik V. The company also pilots a partnered first-of-its-kind cashless digital health offering.

Generics Bulletin

Indian Leaders Begin Unique Collaboration On Molnupiravir

By Akriti Seth 01 Jul 2021

Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India.

Generics Bulletin

Aspen Faces Vaccine Setback In South Africa As Strides Explores Oral COVID Treatment

By Akriti Seth 22 Jun 2021

After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.

Generics Bulletin

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

By Akriti Seth 16 Jun 2021

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Generics Bulletin

New COVID-19 Vaccine Patent Database Launched

By Ian Schofield 11 Jun 2021

As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly accessible resource giving information on the patent status of approved and candidate vaccines.